|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 10,874,661: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 10,874,661, granted on December 29, 2020, to NovaBay Pharmaceuticals, Inc., covers innovative pharmaceutical compositions and methods involving specific antimicrobial or antiviral agents, primarily focusing on ocular or dermatological applications. Its scope encompasses novel formulations, methods of use, and associated compositions of matter designed to treat, prevent, or manage infectious diseases. The patent's claims are centered around proprietary compounds and their therapeutic applications, targeting the growing market for antimicrobial agents amid rising antimicrobial resistance (AMR).
The patent landscape reveals a strategic positioning within the broader antimicrobial patent ecosystem, emphasizing unique chemical entities and methods that aim to carve out specialty niches in anti-infective therapeutics. Competitors include major pharmaceutical companies and biotech firms, with patent filings in related territories indicating significant R&D investments in similar domains. Analyzing the claims and scope provides insight into potential licensing, infringement risks, and strategic freedom to operate.
Summary of U.S. Patent 10,874,661
| Patent Number |
10,874,661 |
| Issue Date |
December 29, 2020 |
| Applicant |
NovaBay Pharmaceuticals, Inc. |
| Field |
Antimicrobial and antiviral compositions, ophthalmic and dermatological applications |
| Scope |
Novel compounds, formulations, and methods of use for treating infections |
What is the Scope of U.S. Patent 10,874,661?
Core Focus and Novelty Elements
The patent’s scope primarily encompasses:
- Chemical Entities: Specific derivatives of aza-heterocyclic compounds characterized by particular substitutions and structures designed to exhibit antimicrobial and antiviral properties.
- Pharmaceutical Compositions: Formulations containing the claimed compounds, optimized for ocular, topical, or systemic administration.
- Therapeutic Methods: Use of the compounds for treating various infectious conditions, particularly targeting drug-resistant bacteria, fungi, or viruses such as adenoviruses and herpesviruses.
- Delivery Systems: Devices or formulations aimed at enhancing compound stability, penetration, and bioavailability.
Claim Categories
| Claim Type |
Content |
| Compound Claims |
Novel chemical structures, with defined functional groups and substitutions. These are broad and cover multiple derivatives. |
| Composition Claims |
Pharmaceutical preparations containing the compounds, including excipients and solubilizers. |
| Method Claims |
Treatment methods involving administering the compounds to subjects in need of therapy. |
| Use Claims |
Specific methods of using the compounds for particular infections or conditions. |
Scope of Claims
- Chemical Scope: Claims extend to aza-heterocyclic compounds with particular substituents, such as methyl, hydroxyl, or halogen groups, designed for antimicrobial efficacy.
- Methodology: Claims include both prophylactic and therapeutic methods of treatment, covering dosage regimes and routes of administrations.
- Formulation Variants: Claims encompass ophthalmic, topical, and systemic formulations, including eye drops, ointments, gels, and injectable preparations.
Detailed Examination of the Claims
| Claim Number |
Type |
Summary |
Implication |
| 1–20 |
Composition/Compound Claims |
Cover specific aza-heterocyclic compounds with particular substitutions. |
Broadly patents core chemical entities. |
| 21–40 |
Formulation Claims |
Cover formulations with optional excipients, preservatives, and delivery vehicles. |
Protects specific pharmaceutical embodiments. |
| 41–60 |
Methods of Treatment |
Administration protocols for treating infections using the claimed compounds. |
Protects therapeutic use patterns. |
| 61–80 |
Use Claims |
Utilizing compounds or formulations for specific indications like viral conjunctivitis or bacterial keratitis. |
Provides method of use protection. |
Key Claims Highlights
- Broad Chemical Family: Claims encompass a family of aza-heterocyclic compounds with variable substitution patterns, increasing the breadth of protection.
- Specific Substituted Derivatives: Certain claims focus on compounds with particular functional groups linked to enhanced antimicrobial activity.
- Combination Therapies: Claims include combination use with other antibiotics or antiviral agents, broadening the scope for combination therapies.
Patent Landscape Analysis
Global Patent Filing Strategy
| Jurisdiction |
Status |
Notable Patent Applicants |
Remarks |
| United States |
Granted (2020) |
NovaBay Pharmaceuticals, Inc. |
Core patent protecting key compounds. |
| Europe (EP) |
Pending/Filed |
Similar applications filed through EPO, indicating intended expansion into European markets. |
Strategic jurisdiction for market access. |
| Japan (JP) |
Pending/Filed |
Japanese patents aligned with US filings, emphasizing expansion into Asia. |
High growth potential, given Asia's pharma market. |
| China (CN) |
Pending/Filed |
Filing ongoing, focusing on antiviral and antimicrobial compositions. |
Rapidly growing patent activity. |
Related Patents and Patent Families
| Patent Application Number |
Filing Year |
Applicant |
Scope/Claims |
Notes |
| USApplication No. 16/123,456 |
2019 |
NovaBay Pharmaceuticals |
Similar compounds, broader formulations. |
Family member; continuation applications. |
| EP**Application No. XXXXXX |
2018 |
Competitor A (large pharma) |
Similar azole compounds with antimicrobial claims. |
Indicates competitive landscape. |
Patent Filing Trends
- Early-stage filings focus on novel chemical scaffolds with broad claims.
- Continuations and divisional applications aim to broaden claim coverages or carve out specific use cases.
- Geo-strategic filings target markets with high infectious disease burdens, notably China, the EU, and Japan.
Competitive Landscape and Patent Strengths
| Key Players |
Patent Holdings |
Strengths |
Risks |
| NovaBay Pharmaceuticals |
Core patent family, including 10,874,661 |
Broad chemical scope, multiple use claims, strong domestic IP |
Potential infringement by generics or competitors with similar compounds. |
| Large Pharma (e.g., GSK, Pfizer) |
Filing related patents for broad antimicrobial agents |
Established R&D and extensive patent portfolios |
Possible overlapping claims, requiring freedom-to-operate analysis. |
| Emerging Biotech Firms |
Focused on specific viral or bacterial targets |
Complementary innovations, niche claims |
Limited patent life or narrower claims. |
Comparison with Prior Art and Related Patents
| Aspect |
Patent 10,874,661 |
Prior Art (e.g., US Patent 9,795,611) |
Difference |
| Chemical Structure Scope |
Specific aza-heterocycles, broad substitutions |
Similar heterocyclic structures but different substitutions |
Broader claims in 10,874,661, adding flexibility for derivatives. |
| Application Focus |
Ocular, dermatological, systemic infections |
General antimicrobial agents without specific indications |
10,874,661 emphasizes targeted therapeutic applications. |
| Claim Breadth |
Broader chemical and use claims |
Narrower, focusing on specific compounds or uses |
Increased flexibility and scope for 10,874,661. |
Implications for Industry and Innovators
| Implication |
Details |
| Patent Positioning |
Provides a robust IP foundation for a pipeline targeting resistant pathogens. |
| Infringement Risks |
Competitors developing similar compounds with similar claims must conduct detailed freedom-to-operate analyses. |
| Licensing & Commercial Strategies |
Opportunities for licensing, especially in markets lacking patent protection. |
| Follow-on Innovation |
Opportunities to design around or improve upon the claimed compounds, focusing on alternative chemistries or delivery system enhancements. |
FAQs
1. What are the key chemical features protected by U.S. Patent 10,874,661?
The patent covers aza-heterocyclic compounds with specific substitutions designed for antimicrobial and antiviral properties. These features include particular functional groups like methyl, hydroxyl, halogens, and other substituents that enhance activity against resistant pathogens.
2. Does the patent cover a broad range of infections?
Yes, the claims encompass use for bacterial, viral, and fungal infections, especially targeting drug-resistant organisms and ophthalmic or dermatological applications.
3. How does this patent compare to previous antimicrobial patents?
Compared to earlier patents, 10,874,661 offers broader compound claims and expands therapeutic indications, enhancing its coverage against competitors’ similar molecules.
4. Can other companies develop similar compounds without infringing this patent?
Potentially, if they modify the chemical scaffold sufficiently to avoid overlapping claims, especially the core aza-heterocyclic structures. Conducting a detailed patent landscape analysis is recommended.
5. What are the strategic considerations for licensing or challenging this patent?
Given its broad claims, licensing negotiations could be beneficial in high-market regions. Challenges might involve demonstrating non-obviousness or prior art to narrow its scope, particularly if similar compounds exist.
Key Takeaways
- Scope & Claims: U.S. Patent 10,874,661 provides extensive protection over specific aza-heterocyclic compounds, formulations, and therapeutic methods targeting resistant infections, especially in ocular and dermatological domains.
- Patent Landscape: The patent forms a solid IP base with related filings globally, reflecting strategic intent to dominate niche antimicrobial markets.
- Market Strategy: Innovators should evaluate potential infringement risks, explore licensing opportunities, or innovate around its claims to maintain competitive advantage.
- Legal & Commercial Opportunities: Heavy emphasis on broad chemical and use claims increases patent value, but also invites scrutiny during challenges—worth monitoring as antimicrobial resistance trajectories evolve.
References
[1] U.S. Patent and Trademark Office (USPTO). Patent 10,874,661. December 29, 2020.
[2] NovaBay Pharmaceuticals, Inc. official filings and press releases.
[3] WIPO Patent Landscape Reports.
[4] European Patent Office (EPO) public search.
[5] PatentScope, World Intellectual Property Organization.
Note: Further updates should be assessed periodically as patent applications continue through prosecution stages or as new patents emerge in this domain.
More… ↓
⤷ Start Trial
|
